---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115800"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:21:00.493920+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025

## Summary
- Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).
- The trial is evaluating Haduvio for the treatment of refractory chronic cough.
- Topline data from the RIVER trial is expected to be reported in the first quarter of 2025.

## SEC filing metadata
- accession: 0000950170-24-115800
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/0000950170-24-115800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/trvi-20241021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115800
- JSON: https://secwatch.observer/filing/0000950170-24-115800.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.